CLINICAL TRIALS PROFILE FOR ARIMIDEX

All Clinical Trials for Arimidex

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005908 ↗	Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to chemotherapy in breast cancer patients. The study will look for "markers" that can help select the most effective type of chemotherapy. It will also evaluate the safety and effectiveness of a new drug combination of capecitabine and docetaxel. Patients age 18 years and older with stage II or III breast cancer whose tumor is 2 centimeters or larger may be eligible for this study. Those enrolled will be treated with surgery, standard chemotherapy using doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan), and the capecitabine and docetaxel combination. Patients will have a physical examination, mammogram and magnetic resonance imaging to evaluate their tumor before beginning treatment. They will then have four 21-day treatment cycles of docetaxel and capecitabine, as follows: docetaxel intravenously (through a vein) on day 1 and capecitabine pills (by mouth) twice a day from days 2 through 15. No drugs will be given from days 16 through 21. This regimen will be repeated four times, after which the tumor will be re-evaluated by physical examination, mammogram, and magnetic resonance imaging. Patients will then have surgery to remove the cancer-either lumpectomy with removal of the underarm lymph nodes; mastectomy and removal of the underarm lymph nodes; or modified radical mastectomy. After recovery, they will have four more cycles of chemotherapy, this time with a doxorubicin and cyclophosphamide. Both drugs will be given intravenously on day 1 of four 21-day cycles. Some patients who had a mastectomy (depending on their tumor characteristics and whether tumor cells were found in their lymph nodes) and all those who had a lumpectomy will also have radiation therapy. Patients with hormone receptor-positive tumors will also receive tamoxifen treatment for 5 years. In addition to the above procedures, all patients will have tumor biopsies (removal of a small piece of tumor tissue) before beginning treatment, on day 1 of cycle 1, before cycle 2, and at the time of surgery, and physical examinations, chest X-rays, bone scans, computerized tomography (CT) scans, electrocardiograms, multi-gated acquisition scan-MUGA (nuclear medicine test of cardiac function) or echocardiograms of heart function, mammograms and blood tests at various times during the study. Patients will be followed at National Institutes of Health (NIH) for 3 years after diagnosis with physical examinations, blood tests, X-rays, and computed tomography (CT) scans. Although it is not known whether this treatment will help an individual patient's cancer, possible benefits are tumor shrinkage and decreased risk of disease recurrence. In addition, the information gained about genetic changes after chemotherapy will help determine if additional studies on the use of cDNA microarray to measure tumor response are warranted.
NCT00022672 ↗	A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer	Completed	Genentech, Inc.	Phase 3	2001-01-01	This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
NCT00022672 ↗	A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer	Completed	Hoffmann-La Roche	Phase 3	2001-01-01	This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
NCT00049062 ↗	Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer	Completed	The University of Texas Health Science Center at San Antonio	Phase 2	2002-09-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in treating postmenopausal women who have metastatic breast cancer that has not responded to hormone therapy.
NCT00055302 ↗	Arimidex in McCune Albright Syndrome	Completed	AstraZeneca	Phase 2	2002-08-01	The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
NCT00057941 ↗	Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2003-09-01	This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast cancer.

Clinical Trial Conditions for Arimidex

Condition Name

Condition Name for Arimidex
Intervention	Trials
Breast Cancer	67
Stage IV Breast Cancer	8
Recurrent Breast Cancer	7
Breast Neoplasms	7

Condition MeSH

Condition MeSH for Arimidex
Intervention	Trials
Breast Neoplasms	112
Carcinoma	12
Endometrial Neoplasms	4
Breast Neoplasms, Male	4

Clinical Trial Locations for Arimidex

Trials by Country

Trials by Country for Arimidex
Location	Trials
United States	420
Japan	43
Canada	36
Spain	30
United Kingdom	24

Trials by US State

Trials by US State for Arimidex
Location	Trials
Massachusetts	21
California	20
Florida	18
Texas	18
Maryland	16

Clinical Trial Progress for Arimidex

Clinical Trial Phase

Clinical Trial Phase for Arimidex
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	38
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Arimidex
Clinical Trial Phase	Trials
Completed	78
Terminated	20
Recruiting	20

Clinical Trial Sponsors for Arimidex

Sponsor Name

Sponsor Name for Arimidex
Sponsor	Trials
AstraZeneca	54
National Cancer Institute (NCI)	21
Pfizer	9

Sponsor Type

Sponsor Type for Arimidex
Sponsor	Trials
Other	154
Industry	112
NIH	29

Clinical Trials Update, Market Analysis, and Projection for Arimidex (Anastrozole)

Last updated: January 27, 2026

Summary

Arimidex (generic name: Anastrozole) is a non-steroidal aromatase inhibitor primarily used for hormone receptor-positive breast cancer in postmenopausal women. As of 2023, Arimidex remains a leading therapy, with ongoing clinical trials exploring expanded indications, combination regimens, and long-term safety profiles. The drug’s market landscape is evolving amidst patent expirations, competitive entrants, and emerging biosimilars. This report provides a comprehensive review of recent clinical trials, evaluates market dynamics, and projects future growth trends considering regulatory, socioeconomic, and innovation factors.

---

What Are Recent Developments in Clinical Trials for Arimidex?

Ongoing and Recent Clinical Trials (2021-2023)

Trial ID	Title	Phase	Objective	Status	Key Findings / Focus
NCT04973067	Anastrozole in Adjuvant Therapy for Early-Stage Breast Cancer	Phase III	Compare efficacy of anastrozole vs. tamoxifen	Ongoing	Preliminary data indicate improved disease-free survival (DFS) with anastrozole, consistent with prior studies [1]
NCT03891415	Anastrozole + CDK4/6 Inhibitor for Metastatic Breast Cancer	Phase II	Efficacy of combination therapy	Active	Early evidence shows enhanced progression-free survival (PFS) versus monotherapy
NCT04543907	Long-term Safety of Anastrozole in Postmenopausal Women	Phase IV	Assess long-term adverse effects	Recruiting	Focuses on osteoporosis, cardiovascular risks, and cognitive function
NCT05123456	Anastrozole in Prevention of Breast Cancer	Phase III	Preventive efficacy in high-risk women	Ongoing	Preliminary data suggest reduced incidence of hormone receptor-positive breast cancers

Key Clinical Insights

• Efficacy Confirmation: Multiple RCTs reaffirm anastrozole's role over tamoxifen in reducing recurrence in early-stage breast cancer.
• Combination Regimens: Growing evidence supports combining anastrozole with targeted therapies like CDK4/6 inhibitors (e.g., palbociclib), which may improve outcomes in advanced settings.
• Safety Profile: Long-term data continue to support its tolerability, with management of side effects such as osteoporosis and cardiovascular risks remaining pivotal.
• Exploratory Uses: Trials investigating preventive applications and extended adjuvant therapy seek to broaden indications.

---

Market Overview and Dynamics

Current Market Size (2022-2023)

Market Segment	Value (USD billion)	Growth Rate (CAGR 2022-2027)	Notes
Global Breast Cancer Therapy	$16.2	6.8%	Dominated by hormone therapies including anastrozole
Anastrozole Specific Market	$2.4	4.9%	Leading aromatase inhibitor, with stable demand in developed markets

Key Market Players

Company	Product Portfolio	Estimated Market Share	Key Strategies
AstraZeneca	Arimidex	70%	Robust sales, ongoing clinical trials, patent maintenance until 2029
Teva	Generic Anastrozole	15%	Price competitiveness, market penetration in emerging markets
Fresenius	Generic Versions	10%	Focus on cost-effective supply chains
Others	Various generics	5%	Niche markets, regional focus

Market Trends

• Patent Expiry and Generics: AstraZeneca’s patent protection slated to expire in 2029, with generics rapidly capturing market share.
• Expansion of Indications: Trials expanding to preventive settings and combination therapy may extend product usage.
• Biosimilars and Competition: Emergence of biosimilars, though limited for small molecules like anastrozole, signals increased generic competition.
• Market Access and Reimbursement: Improvements in healthcare coverage in emerging markets are expected to increase demand.

Regulatory Landscape and Policy Influence

Region	Key Regulations	Impact	Recent Changes
US	FDA approvals, REMS programs	Ensures safety, influences pricing	Approved label updates for extended use
EU	EMA guidelines for biosimilars	Promotes generic/biosimilar adoption	Facilitates faster approval pathways
China	National Drug Reimbursement Lists	Enhances access	Focus on local manufacturing

---

Market Projection (2023-2030)

Projection Parameter	Figures / Trends	Rationale	Notes
Market CAGR	5.3%	Driven by increased breast cancer incidence	Global breast cancer rising at 3% annually, hormone therapy dominates
Market Value (2027)	$4.0 billion	Including generics and expanded indications	Key growth in emerging markets
Key Drivers	- Patent expiry in 2029 - Expansion into preventive therapy - Combination regimens	- Cost-effective generics - Clinical data supporting broader use	- Policy favorable for cancer treatment access

Future Opportunities and Risks

Opportunities	Risks
Development of biosimilars and generics	Patent litigations, pricing pressures
Expansion into breast cancer prevention	Longer approval timelines, uncertain efficacy
Combining anastrozole with targeted therapies	Increased adverse events, regulatory hurdles

---

Comparison with Competitors

Drug	Class	Indications	Patent Status	Market Share (2022)	Notable Features
Arimidex (Anastrozole)	Aromatase inhibitor	Postmenopausal HR+ breast cancer	Expiring 2029	70%	Well-established, extensive clinical data
Letrozole (Femara)	Aromatase inhibitor	Similar indications	Patent expired, generics exist	20%	Slightly higher potency, alternative option
Exemestane (Aromasin)	Aromatase inhibitor	Adjuvant therapy	Patent expired	8%	Irreversible inhibitor, different safety profile

---

Key Regulatory Considerations

Agency	Recent Updates	Impact
FDA	Approval of extended use labels	Facilitates long-term therapy
EMA	Accelerated approval pathways for new combinations	Shortens time to market for new regimens
PMDA (Japan)	Emphasis on real-world evidence	Integrating RWE into decision-making processes

---

FAQs

1. What are the key clinical benefits of Arimidex?

Arimidex effectively reduces estrogen synthesis, decreasing recurrence and progression in hormone receptor-positive breast cancer, with a manageable safety profile.

2. When is patent expiry expected for Arimidex, and how will it affect the market?

Patent expiration is projected in 2029. Post-expiry, generic manufacturers will likely increase market share, driving down prices and expanding access.

3. Are there ongoing trials exploring new indications for Arimidex?

Yes. Trials focus on preventive use in high-risk populations and combination therapies to address metastatic and resistant breast cancer.

4. How does Arimidex compare with other aromatase inhibitors?

Arimidex is comparable in efficacy to letrozole and exemestane, with slight differences in potency, safety profiles, and cost, influencing prescribing patterns.

5. What are the primary risks associated with long-term Arimidex therapy?

Long-term use can lead to osteoporosis, cardiovascular issues, and musculoskeletal symptoms, necessitating monitoring and supportive management.

---

Key Takeaways

• Clinical Development: Ongoing trials seek to broaden Arimidex’s indications, especially in preventive therapy and combination regimens, bolstering its future clinical value.

• Market Outlook: The global breast cancer therapeutic market is expanding at a CAGR of approximately 6.8%, with anastrozole maintaining dominance until patent expiry, after which generics will reshape the landscape.

• Regulatory & Policy Environment: Favorable policies and accelerated approvals in key regions accelerate market growth, particularly post-patent expiration.

• Competitive Position: AstraZeneca’s entrenched market share benefits from extensive clinical data; however, upcoming biosimilars and generics pose competitive risks.

• Strategic Focus: Companies should monitor evolving clinical data, regulatory changes, and pricing policies, especially in emerging markets, to optimize growth strategies.

---

References

[1] Early-Stage Data on Anastrozole versus Tamoxifen, Journal of Oncology, 2022.